International cannabis company jumps into the global 57 billion dollar cannabis market. Phoenix Life Sciences International Limited (OTCMKTS: PLSI) and the international cannabis market set to explode.
With cannabis stocks moving back into the spotlight in the heat of incredible money flows and market action over recent weeks, we have been obsessively looking out for sharp plays that the crowd has missed – stocks that fit a top-tier description, but that haven’t been picked up yet in the markets.
These stocks offer the most potential right now as we see it. And PLSI is the current king of that hill according to our analysis.
Learn More About PLSI at your brokerage today!
The company is one of the very few integrated players, with an end-to-end operational strategy that covers everything – farm to table – from cultivation of cannabis to distribution of refined products that span a fast-tracked pipeline attacking $1.14 trillion in total market footprint.
The company is also already global in its strategy, which may set it apart as well.
Company: Phoenix Life Sciences International Limited
Latest News: http://finance.yahoo.com/q/h?s=PLSI+Headlines
Company Website: https://plsi.co/
- PLSI is possibly the most impressive cannabis play that the crowd hasn’t found yet.
- PLSI is already working with federal governments and national healthcare systems.
- PLSI is starting to see major topline growth, with quarterly y/y revs increasing sharply.
- PLSI is coming off an RSI trough under 51, pointing to a massively oversold stock now heading back the other way.
- PLSI just recorded a MACD Bullish reversal, suggesting a technical change in trend.
- PLSI has developed a deep pipeline of cannabis treatment options addressing some of the biggest healthcare markets.
Phoenix Life Sciences International Limited (OTCMKTS: PLSI) is an adaptive healthcare solutions company. PLSI is in business to advance research and integrate programs and manufacturing of products that target and treat diabetes, pain, cancer, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders.
The company strives to create partnerships and integrate these programs for human health into communities worldwide as part of its Global Health Initiative.
According to company materials, “Phoenix Life Sciences International Limited is headquartered in Denver, Colorado. Over the past four years, many of our partner organizations have worked hard to develop and access a broad range of industry and pharmacology specialists. The partnership includes botanists, biologists, industrial and organic chemists, medical doctors, researchers, packagers and distributors. We are delighted to announce that in September 2018 we merged many of these partnerships and affiliations together under the name Phoenix Life Sciences International Limited. Without the support and collaboration of many individuals, this vision wouldn’t have been realized and we thank them for their global vision.”
As far as recent catalysts, the company just announced its common stock is now publicly traded in the United States, trading under the symbol OTC: PLSI and released some initial statements on its global production strategy for cannabinoid-based healthcare solutions.
According to the release, Phoenix Life, which is a consolidation of multiple domestic and international businesses including Stem BioScience, Inc., Blue Dragon Ventures, along with the MediJane brand, aims to be the premier global healthcare company that changes the way that many diseases and conditions are treated around the world.
“We are confident that we will be able to impact the health and wellbeing of millions of people around the world with our highly-sophisticated cannabis derived formulations and our unique production and distribution models,” said Martin Tindall, incoming Chief Executive Officer of Phoenix Life Sciences International. “I am excited to help guide the company to success and remain committed to the vision of life-enhancement through better healthcare.”
Following that announcement, the company also hit the wires to provide an update on the completion of merger documents with the Secretary of State in Nevada, as well as appointed a new renowned audit firm and retired a substantial amount of convertible debt.
As a part of the final steps of its merger that created Phoenix Life Sciences International Limited, documents were processed through the Secretary of State for Nevada. The documents, including form and certificate of merger, were received back by the company, leaving only this week’s boards of directors’ appointments in the finalization of the company merger.
In other words, it’s all systems go for PLSI at this point.
Which brings us to this very interesting chart. Shares of the stock have started to move with some bullish potential under the surface of the tape.
The stock recently broke out above its 200-day simple moving average on increasing volume. As noted above, the stock has one of the smallest trading floats we have ever come across (under 25k shares). That means any influx of buying interest will send this to the moon.
You can see a good example of this back in January of this year, when PLSI went from $2.50/share to $90/share in 6 days. That’s no joke. And it could happen from here given this tiny float and the increasing attention being paid to the cannabis space.
Remember, this is one of the only true global integrated cannabis players out there.
Phoenix Life Sciences International Limited (OTC:PLSI) is creating a global platform for the re-introduction of organic, plant based pharmaceuticals and programs for creating healthcare solutions and reducing total cost of national healthcare programs
“Our business is to advance research and integrate programs and manufacturing of products that target and treat; diabetes, pain, cancers, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders.
Creating partnerships for integrating these programs for human health into communities worldwide as part of our Global Health Initiative. Working with developing nations on programs to improve affordable healthcare and creating industry.
Phoenix Life Sciences uses organically produced plants, including cannabis, extracts the purist of active ingredients and encapsulates them for maximum bio availability and efficacy. Providing a patient-centric alternative to the low efficacy and the high side effects of conventional pharmaceuticals. Giving doctors and their patients an easy to take, easy to manage, accurately dosed natural healthcare solution.
Phoenix Life Sciences International is targeting to build production to service over 2.5 million patients over the next 5 years.”
Key Team Members:
Martin Tindall, CEO and Founder
Tindall has an extensive career in large scale organizational change. His career focus has been in the integration of technology with international trade and finance. Initially trained in accounting and commercial and company law, he has held various roles including Chief Information Officer at Bartercard, Executive Director of Kronos International Investments and particularly enjoyed environmental projects that deliver sustainability.
Starting Phoenix in 2013, after the death of his father from chemotherapy treating his pancreatic cancer, Tindall is devoted to providing advancement in the treatment of cancer, diabetes and other diseases using safe, non-toxic, plant based pharmaceutical solutions.
Janelle Marsden, Managing Director
Marsden has held senior roles across many industry sectors. Trained at a master’s level in construction, architecture and finance, she has been awarded senior roles over the past 20 years in both the public and private sector. Having lived in Australia, U.S. and Italy, Marsden has worked on large scale implementation projects and managed large agriculture developments. Marsden’s skills include agricultural grow, product implementation, organization and marketing. She has been the chair and board member of tourism, economic development and food and wine entities and has demonstrated her ability to drive and grow industries from the ground up. Marsden will also directly over see the infrastructure developments and ensure that Phoenix continues to meet its environmental, financial, timely and quality outcome.
Learn More About PLSI at your brokerage today!
This report is for information purposes only and is neither a solicitation or recommendation to buy nor an offer to sell securities. MMJreporter is not-a-registered-investment-advisor. MMJreporter is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. MMJreporter accepts no liability for any losses arising from an investor’s reliance on the use of this material. MMJreporter has been compensated 25k for coverage of this stock by Phoenix Life Sciences International Limited this month. MMJreporter and its affiliates or officers currently hold 395,000 shares of this stock. MMJreporter and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. MMJreporter will not update its purchases and sales of these stocks in any future postings on MMJreporter’s websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words “may”, “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” ” project,” and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *MMJreporter does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment..
California cannabis stocks take off after new July 1 regulations
Stocks jump as much as 105% in 30 days…and still rising!
Undervalued Chemesis International Inc. (OTC: CADMF / CSE: CSI) is the single best way for investors to play this fast-moving scenario.
While most cannabis investors are still looking to Canadian producers for big stock profits, the California pot market is starting to rise like a tsunami.
The savviest investors are jumping from Canadian cannabis stocks to catch the California wave. If you’re out for big profits, it’s time for you to jump in too.
Consider this. In the 30 days ending September 11, these California-focused cannabis stocks have given their investors returns that beat the market by an average of 29-to-1.
Returns since early August:
Chemesis Intl (CADMF) 150%
Solis Tek (SLTK) 105%
CannaRoyalty (CNNRF) 58%
MedMen (MMNFF) 55%
Sunniva (SNNVF) 34%
S&P 500 2%
It’s the beginning of the biggest new bull market today
No other industry today is recording these kinds of returns. Not technology, not Internet retail, not industrials or oil and gas. California-focused cannabis stocks are out-performing nearly everything else in the market, and this is just the beginning.
Legal sales of recreational cannabis began in California on January 1, 2018. The state gave sellers six months to become compliant with new regulations. By July 1 they had to be in strict compliance on purity testing, safety packaging, and content labeling of products.
Plenty failed to meet the stringent standards, and the state started shutting them down. But those that are compliant have seen their stocks soar as laggards are weeded out.
These companies are benefitting from what will soon be the world’s biggest legal cannabis market.
California will soon eclipse entire Canadian cannabis market
California is already the largest cannabis market in the world – by a long shot. ArcView Market Research estimates that the legal and illegal cannabis market in the state surpassed $8 billion in 2016. Newsweek puts the figure even higher at $13.5 billion. The California legal medicinal market alone is responsible for an estimated 62% of US sales.
Now, with legalization, much of the illegal sales will transfer to legal dispensaries, contributing to a growth rate for legal cannabis that is expected to compound at an annual rate of 23%. By comparison, the entire Canadian cannabis market is $4.2 billion.
It’s easy to see why California legal sales will surpass all of Canada’s. More people live in California than in all of Canada. And California’s GDP is nearly three times larger than Canada’s. That means there are more people to use cannabis and more money to buy larger quantities of it.
To put California’s massive cannabis market size in perspective, experts believe legal cannabis sales could surpass beer sales in the state by the end of 2019, topping $5 billion, and $6.5 billion by 2020.
All of which is why California-focused cannabis companies will grow the largest and will dominate the market for years to come.
For comparison, take a look at how cannabis legalization in Canada fueled investor profits.
Profits as high as 9,755%
Though medicinal cannabis has been legal in Canada since 2001, until 2014 it could only be purchased through the government. Laws were relaxed in 2014 to allow sales through private companies. That triggered a gold rush, and produced the first wave of cannabis stock millionaires. Investors saw returns as high as 9,755% in Abattis Bioceuticals and 9,150% in United Cannabis.
There’s no question that Canada’s cannabis stocks have made investors rich. In the last 12 months the Canadian Marijuana Index has shot up 291%, despite a dramatic pullback in January. The last three years has seen a 1,437% rise.
But for Canada-focused cannabis companies, the biggest gains are behind them. The market leaders have already been established. Now you will see a wave of consolidation as second-tier companies are bought up or go out of business, unable to compete with the geographic range and low production costs of the leaders.
That’s why savvy investors are turning to California.
A remarkably uncrowded marketplace
Savvy investors are buying up stocks like Solis Tek (SLTK), CannaRoyalty (CNNRF), MedMen (MMNFF), Chemesis International (CADMF), and Sunniva (SNNVF).
These are not only the dominant players in California, they are among the few players there. One of the reasons is because the new rules are making it harder for new companies to find their financial footing, with licenses and compliance for everything from product potency and zoning requiring the expenditure of tens of thousands of dollars. “Since all of the regulations went into place, now it takes a few hundred thousand to a few million to start,” said Kimberly Cargile, CEO of Sacramento retailer A Therapeutic Alternative.
Morgan Paxhia, founder of Poseidon Asset Management, notes that there are thousands of sellers in the state that have been put out of business because they don’t have the capital or expertise to meet regulatory requirements.
That leaves the enormous California market to a handful of companies that can afford the kind of investment required. Venture capital companies “want you to be holding several half-acre or 1-acre permits and licenses to even think about investing,” says one grower. “Most of the bigger guys, a half-acre grow isn’t going to make them the kind of money they want to make. They want something extremely large.”
One cannabis company that has what it takes to attract the kind of venture capital necessary to be a major player is Chemesis International (OTC: CADMF / CSE: CSI).
Deep-pockets challenger aims to be California’s biggest cannabis company
On August 7, 2018 Chemesis announced the finalization of a draw-down $25 million equity financing deal with Alumina Partners, a New York-based private equity firm. The financing is at the sole discretion of Chemesis, allowing the company to access funds as needed.
The financing is designed to protect shareholder value while the company aggressively grows its market share. Such major investments are rare for early stage companies, and serves as a validation of Chemesis’ business plan and growth strategy.
Terms of the deal allow Alumina Partners the purchase of up to $25 million in Chemesis units, consisting of one common share at a 15-25% discount to market price, and one purchase warrant at a 50% premium over market price, all at the exclusive discretion of Chemesis. There are no upfront fees or interest associated with the use of the financing.
Such robust financing is rare for cannabis companies doing business in California. For one thing, cannabis is still illegal on the Federal level. This has stopped many venture capitalists from wanting to participate in the market.
However, the tide is rapidly turning. Casa Verde Capital says that “the cannabis industry will be among the most compelling investment themes of our generation.”
Americans overwhelmingly support legalization
President Trump has promised to protect states that have legalized cannabis. His position was made clear in April of 2018 when he told Colorado Senator Cory Gardner that the state’s cannabis industry would not be targeted, despite the objections of Attorney General Jeff Sessions.
What’s more, in April, the US House of Representatives proposed legislation to loosen federal cannabis regulations. Even formerly staunch opponents are coming around, including former House Speaker John Boehner and conservative Republican congressmen Dana Rohrabacher and Tom Garrett.
More than half of US states allow some form of cannabis use, either medical or medical and recreational. By the end of 2018 that number could be more than three quarters.
They are responding to the will of the people: Americans, including Republicans, overwhelmingly support legalization.
For these reasons and more, venture capital company Alumina Partners bet big on Chemesis International. What they saw was a company that could dominate its market.
Says CEO Edgar Montero, “We are very well capitalized at this point. We have control of our destiny, which is very, very refreshing for our shareholders because now the leverage is on our side.”
Chemesis International (OTC: CADMF / CSE: CSI): First-mover advantage in the enormous California market
In marketing strategy, there’s a term called “first-mover advantage” that offers rare benefit to those companies that can claim it. It’s when a company is among the first key players in a new market or a new industry, and therefore are able to establish themselves before being overrun by competitors.
These companies are able to establish strong brand recognition, shore up the best sources of funding, and build a loyal customer base simply because there aren’t any competitors in the way during their first few years of operation.
Chemesis is one of the few fully compliant first movers in the California market. The company is vertically integrated, which means they are involved in every stage of the cannabis market from seed to sale. That includes cultivation, product manufacturing, branding, distribution, and retail.
The company also owns a state-of-the-art, fully state-compliant facility in Cathedral City, California that provides legal cannabis to a network of dispensaries throughout California.
Chemesis also owns 80% of SAP Global, a California producer with a 2,000 pound processing capacity that can yield as much as 200 pounds of compliant cannabis oil per day, which is substantial. SAP is known for its high quality, and has been the recipient of 26 awards in the past five years.
The producer is intended to provide Chemesis with a consistent revenue stream as the company invests its resources in aggressive growth strategies.
Chemesis also owns Desert Zen, a state-compliant cannabis manufacturing, packaging, distribution, and transport company with a large existing network of dispensaries and distributors throughout California.
Importantly, Desert Zen is able to track all products, monitor safety, and ensure that all seed-to-sale laws are followed throughout the entire supply chain.
Chemesis projects annual revenue from California operations of $61.5 by 2022, with a net income of $27.2.
But California isn’t the company’s only market where they have first-mover advantage.
Chemesis expands into second new market
Part of the company’s unique strategy is to be first-to-market as cannabis legalization expands globally. That was how they were able to establish an early presence in California. And it is why they have now expanded into Puerto Rico.
With medicinal cannabis now legal in Puerto Rico as of 2017, Chemesis has become a first-mover in that market. More than 20,000 patients have registered for medical cannabis in the first year in the territory.
Secretary of Health Rafael Rodriguez Mercado says that the market is “growing exponentially,” with approximately 500 new patients per week. The US territory’s treasury secretary says medical cannabis could generate up to $100 million a year in sales taxes.
In August 2018 Chemesis purchased an 80% interest in Natural Ventures PR LLC, a seed-to-sale medicinal cannabis company based in Caguas, Puerto Rico. Natural Ventures has operated since 2017, and is licensed to cultivate 100,000 square feet of cannabis.
Currently the company owns a 35,000 square foot manufacturing facility, and is producing oil-based products as well as edibles and other cannabis products. (Puerto Rico law restricts medicinal cannabis products to capsules, extractions, lotions, patches, edibles, flower, and oils.)
Chemesis expects their Puerto Rico operations to provide a significant revenue stream totaling $6.7 million in revenue by 2022, with a net income of $2.8 million.
Don’t miss your chance for oversize profits from California’s new recreational cannabis market
On July 1, compliant California cannabis companies put the pedal to the medal. With thousands of non-compliant sellers being wiped from the market, those that remain – the ones with deep-pockets financing and fully compliant facilities and products – will quickly rise to the top.
There are only a small number of them, like Solis Tek (SLTK), CannaRoyalty (CNNRF), MedMen (MMNFF), Chemesis International (OTC: CADMF / CSE: CSI), and Sunniva (SNNVF).
Chemesis International has distinct advantages. If you’re eager to get your share of big cannabis profits, take a close look at Chemesis (OTC: CADMF / CSE: CSI) today. And remember to always do your own due diligence.
High Times Holding Co. is on a Mission and Wants You to Be a Part of It
With such intense attention on the cannabis sector over the last few months, it should come as no surprise that the industry’s mascot, and perhaps its heart and soul, is looking to cash in as well. High Times, the iconic magazine and media property is looking to go public.
The actual entity in question here is High Times Holding Co., which was formerly known as Trans-High Corporation and changed its name to High Times Holding Co. in June, 2017. You probably know it as ‘that marijuana magazine’. The company has actually been around for nearly 45 years. And it’s apparently high time for a move onto the public markets.
Going to the Show
After filing for an IPO in January of this year, those plans were put on hold when it looked like prospects for raising enough in the deal soured. However, in June, the company announced it would be “launching an equity crowdfunding campaign ahead of its application for an initial public offering on Nasdaq later this year.”
Adam Levin, Chief Executive Officer of High Times said, “The campaign is intended to bolster the valuation of High Times Holding Corp while offering non-institutional investors greater access to shares than they would have in an IPO.”
For the offering, High Times set a price of $11 per share, 10% below the price the company expects the shares to trade on Nasdaq.
The company recently acknowledged that it would have to raise at least $14.7 million from the offering to live up to the Nasdaq’s stringent listing standards. They already have about $12.5 million committed from more than 9,000 investors.
Initially, in order to help open the spigots, the company suggested it would accept investments in Bitcoin. However, that plan was changed – without clear explanation. At this point, High Times will take fiat only, but through any means possible (checks, credit cards, ACH or wire transfers), as it strives to raise funds for subscription to is Reg-A+ share offering.
So, what do they need to get to the magic number? Remember, the parent company has a troubled balance sheet, with lots of debt on hand. So far, over half of its raised funds have gone to pay off creditors.
The answer is: more media exposure – it boils down to “Buzz”.
How to Get High
To get that done, the company recently entered into a “no cash” deal with iHeartMedia Inc (OTCMKTS:IHRTQ), a diversified media and entertainment company with a broad mainstream reach. According to the Wall Street Journal, iHeartMedia Inc “will trade up to $10 million worth of advertising inventory for a roughly 5% stake in the publisher of High Times, the 44-year-old marijuana magazine, offering the biggest U.S. radio broadcaster access to the nation’s growing number of cannabis consumers.”
“Cannabis at the end of the day is mainstream,” said High Times Chief Executive Adam Levin. “And iHeart has a huge mainstream appeal.”
In other words, Levin sees this as the deal that can take the High Times investment opportunity to the masses in a big enough way to generate what amounts to a rescue bid for ownership that is big enough to get the company public through the Reg A+ route and in position to meet Nasdaq listing criteria.
Given the buzz right now in front of the full legalization of the Adult-Use market in Canada expected to take effect later this month, and the $5 million to $10 million of ad inventory committed from iHeart, this is the right time to try this unique strategy.
What investors will be left with over the longer term is another question altogether.
Where to Next for Leafbuyer Technologies Inc (OTCMKTS:LBUY)?
If you want to know what it feels like to ride a roller coaster, just ask a Leafbuyer Technologies Inc (OTCMKTS:LBUY) shareholder. The stock has been all over the map over the past three weeks but now sits basically in the middle of a wide whipsaw range with roots down under $0.70 from late September and branches poking above $2.30. It’s enough to make the head spin.
Which way will it go from here? Well, if the company’s sales are the determining factor, then the answer could come from its latest announcement of booming quarterly sales, with results up 67% in the period ending September 30th, 2018, compared to the same period the previous year. “We recently reported our FY sales results that ended on June 30th with a 42% growth rate. This recent quarter significantly increased that acceleration. The average monthly spend per customer is steadily increasing and we are seeing higher demand for our products in all of the legal states we cover,” said Leafbuyer Chairman and CEO, Kurt Rossner.
Leafbuyer Technologies Inc (OTCMKTS:LBUY), according to corporate communications, is “one of the most comprehensive online sources for cannabis deals and information. Leafbuyer works alongside businesses to showcase their unique products and build a network of loyal patrons. Leafbuyer’s national network of cannabis deals and information reaches millions of consumers every month. Leafbuyer is the official cannabis deals platform of Dope Media, LA Weekly, and Voice Media Group.”
The company is a technology-based cannabis marketing firm based in Greenwood Village, CO. The company’s website, leafbuyer.com is one of the most comprehensive online source for cannabis deals and specials, Leafbuyer.com connects consumers with dispensaries. Leafbuyer works alongside businesses to showcase their unique products and build a network of loyal patrons.
Leafbuyers national network of cannabis deals and information reaches millions of consumers monthly. Leafbuyer is the official cannabis deals platform of thecannabist.co (owned by the Denver Post) and westword.com.
The company also operates one of the largest cannabis-based employment boards in the industry and has partnered with large cannabis content sites that are included in their distribution network.
Leafbuyer Technologies Inc (OTCMKTS:LBUY) generated sales of $342K, according to information released in the company’s most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of 19.2% on the top line. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($376K against $1.3M, respectively).
Trying to Push the Squeeze
LBUY, as noted, just declared itself in a top-line boom. It will be interesting to see if shares can follow that lead.
“We continue to make investments in future product development. Leafbuyer delivers solutions that drive more value to our customers. Our new product bundles are being well received by the market. We not only drive consumers to dispensaries, we continue to monetize that relationship month after month,” said Leafbuyer COO, Mark Breen.
Shares of LBUY, as noted above, have been riding the roller coaster over the past month, but mostly upward, rallying roughly 30% in that time on strong overall action. Furthermore, the listing has witnessed a pop in interest, as transaction volume levels have recently pushed nearly 230% over the long run average.
This is particularly important with the stock trading on a float that is tight at just 18.3M shares. It’s something the veterans know to key on: a jump in average daily transaction volume in a stock with a restricted float can unleash fireworks as supply is squeezed in the scramble to buy or cover.
Digipath Inc. (OTCMKTS: DIGP) Announce Significant Milestones On Development Of GroSciences Hemp-Test Kit
Post Views: 327 Digipath Inc. (OTCMKTS:DIGP) has announced that its GroSciences subsidiary has made substantial progress in the development of...
Harvest Health & Recreation Inc (OTCMKTS:HRVSF) Launches Expands Its Footprint In Florida With New Medical Marijuana dispensary in Gainesville
Post Views: 358 Harvest Health & Recreation Inc (OTCMKTS:HRVSF) recently announced that it launched a new outlet in Gainesville, making...
Harvest Health & Recreation Inc (OTCMKTS:HRVSF) Gets Greenlight To Expand Its Foreign Private ISSUER Threshold
Post Views: 328 Harvest Health & Recreation Inc (OTCMKTS:HRVSF) revealed earlier this month that its Board of Directors has approved...
Generex Biotechnology Corporation (OTCMKTS:GNBT) Adds MediSource Partners And Pantheon Medical To Its NuGenerex Family Of Subsidiaries
Post Views: 286 Generex biotechnology Corporation (OTCMKTS:GNBT) has welcomed MediSource Partners to its family of subsidiaries and introduced Pantheon Medical...
CBD Unlimited Inc. (OTCMKTS:EDXC) Enhances Its Convenience Store Program Targeting 300 Stores
Post Views: 274 CBD Unlimited Inc. (OTCMKTS:EDXC), formerly Endexx Corporation, has announced an enhanced convenient store launch program. The provider...
Cronos Group Inc. (NASDAQ:CRON) Spends $300 Million On CBD Skincare Businesses
Post Views: 260 Cronos Group Inc. (NASDAQ:CRON) has not had the best of runs in recent months, after starting the...
Elev8 Brands, Inc. (OTCMKTS:VATE) A Potential Break Out Play On Sales Growth Boost
Post Views: 277 Elev8 Brands, Inc. (OTCMKTS:VATE) stock is a potential break out play as a flurry of positive developments...
Medical Marijuana Inc. (OTCMKTS:MJNA) Eyes Fresh Gains On Improving Fundamentals
Post Views: 173 Medical Marijuana Inc. (OTCMKTS:MJNA) bounce back from all-time lows continues to gather pace on improving fundamentals. Investor’s...
Sugarmade Inc. (OTCMKTS:SGMD) Turns To Hemp Production To Reinvigorate Growth Prospects
Post Views: 180 Sugarmade Inc. (OTCMKTS:SGMD) has made a strategic investment in Hempistry as it tries to reinvigorate its growth...
Auxly Cannabis Group Inc (OTCMKTS:CBWTF) Acquires 46% Stake In Curative Cannabis And Agrees to Fund Cannabis Cultivation Facility To Produce Ultra Premium Cannabis
Post Views: 179 Auxly Cannabis Group Inc (OTCMKTS:CBWTF) has entered a deal to take over a 46% stake in Curative...
Health3 years ago
Medical Marijuana Inc (OTCMKTS:MJNA) Enters Mexico With Hemp Oil
Uncategorized2 years ago
Study Unveils Hemp Could Treat These 10 Chronic Conditions
PROFILES1 year ago
For the Next Wave of Marijuana Profits, Look to Real Estate
PROFILES12 months ago
California cannabis stocks take off after new July 1 regulations
Business12 months ago
Aurora Cannabis Inc (NYSE:ACB) Sets Out for Global Domination with ICC Move
Business2 years ago
Will McKesson Make Maricann Canada’s Next Unicorn Stock?
Business1 year ago
New Age Beverages Corp (NASDAQ:NBEV) Gears Up for a Big Week
Business1 year ago
Why Namaste Technologies Inc (OTCMKTS:NXTTF) Could be Set for a Squeeze